B
Polycystic ovary syndrome
Comorbid ConditionsDisease / conditionriskpartially modifiable
37
evidence score
Also known as: pcos, polycystic ovary
PREVENT status
Not a PREVENT input variable.
Causal support
trial evidence
Score components
lit volume: 12.6meta-analyses: 11.6trials: 12.7genetic: 0MR bonus:
References (17)
3 meta-analyses / systematic reviews- METAMetabolomics Signatures of Atherosclerosis in Cardiovascular Disease: A Narrative Systematic Review. — Journal of clinical medicine 2025 · PMID 41303064
- META2023 International Evidence-Based Polycystic Ovary Syndrome Guideline Update: Insights From a Systematic Review and Meta-Analysis on Elevated Clinical Cardiovascular Disease in Polycystic Ovary Syndrome. — Journal of the American Heart Association 2024 · PMID 39119982
- METALong-term cardiometabolic disease risk in women with PCOS: a systematic review and meta-analysis. — Human reproduction update 2020 · PMID 32995872
- Polycystic ovary syndrome in 2025-insights and innovations. — Fertility and sterility 2025 · PMID 40992713
- Gut Microbes in Polycystic Ovary Syndrome and Associated Comorbidities; Type 2 Diabetes, Non-Alcoholic Fatty Liver Disease (NAFLD), Cardiovascular Disease (CVD), and the Potential of Microbial Therapeutics. — Probiotics and antimicrobial proteins 2024 · PMID 38647957
- Women, lipids, and atherosclerotic cardiovascular disease: a call to action from the European Atherosclerosis Society. — European heart journal 2023 · PMID 37611089
- Polycystic Ovarian Syndrome: a Risk Factor for Cardiovascular Disease. — Current atherosclerosis reports 2023 · PMID 38048007
- Polycystic ovary syndrome: a "risk-enhancing" factor for cardiovascular disease. — Fertility and sterility 2022 · PMID 35512976
- Causal relationship between polycystic ovary syndrome and coronary artery disease: A Mendelian randomisation study. — Clinical endocrinology 2021 · PMID 34524719
- Gestational diabetes mellitus - A metabolic and reproductive disorder. — Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2021 · PMID 34560536
- Metabolically Healthy Obesity (MHO) vs. Metabolically Unhealthy Obesity (MUO) Phenotypes in PCOS: Association with Endocrine-Metabolic Profile, Adherence to the Mediterranean Diet, and Body Composition. — Nutrients 2021 · PMID 34836180
- Metformin for Cardiovascular Protection, Inflammatory Bowel Disease, Osteoporosis, Periodontitis, Polycystic Ovarian Syndrome, Neurodegeneration, Cancer, Inflammation and Senescence: What Is Next? — ACS Pharmacology & Translational Science 2021 · PMID 34927008
- Cardiovascular Disease in Women: From Pathophysiology to Novel and Emerging Risk Factors. — Heart, lung & circulation 2020 · PMID 32843293
- The TRIB3 Q84R polymorphism, insulin resistance and related metabolic alterations. — Biochemical Society transactions 2015 · PMID 26517932
- Influence of race/ethnicity on cardiovascular risk factors in polycystic ovary syndrome, the Dallas Heart Study. — Clinical endocrinology 2015 · PMID 26608823
- Lack of Exercise Is a Major Cause of Chronic Diseases — Comprehensive physiology 2012 · PMID 23798298
- Metabolic syndrome. — Singapore medical journal 2011 · PMID 22173246
Clinical trials (18)
| NCT | Title | Status | Type | Interventions |
|---|---|---|---|---|
| NCT05966792 | The Clinical Efficacy and Mechanism of SGLT2 Inhibitors Treating Polycystic Ovary Syndrome by Modulating the Nod-like Receptor Protein 3 Inflammasome | COMPLETED | INTERVENTIONAL | SGLT2 inhibitors, metformin |
| NCT05601336 | Effect of Sodium Glucose Cotransporter-2 Inhibitors on Metabolic, Hormonal and Clinical Parameters in Infertile Women With Polycystic Ovary Syndrome | UNKNOWN | INTERVENTIONAL | Dapagliflozin 5 MG, Metformin Hydrochloride 1000 MG, Dapagliflozin/Metformin |
| NCT06610812 | KETOGENIC MEDITERRANEAN VERSUS HYPOCALORIC BALANCED DIET ON Added to Aerobic Exercises POLYCYSTIC OVARIAN ADOLESCENTS | COMPLETED | INTERVENTIONAL | KETOGENIC MEDITERRANEAN diet, hypo-caloric diet:, moderate aerobic exercises |
| NCT04876027 | Dulaglutide and Calorie Restrict Diet (CRD) in Overweight/Obese Patients With Polycystic Ovary Syndrome | COMPLETED | INTERVENTIONAL | GLP-1 RAs, calorie restricted diet |
| NCT04973891 | Canagliflozin Administration in Non-diabetic Women With Polycystic Ovarian Syndrome | COMPLETED | INTERVENTIONAL | Canagliflozin combined with metformin, metformin |
| NCT04700839 | The Efficacy of Canagliflozin Versus Metformin in Women With Polycystic Ovary Syndrome: A Randomized, Open Label Trial | COMPLETED | INTERVENTIONAL | SGLT2 inhibitors, Metformin |
| NCT04213677 | Efficacy and Safety of Dapagliflozin in Polycystic Ovary Syndrome: a Multicentre, Randomized, Placebo-controlled Trial | COMPLETED | INTERVENTIONAL | Dapagliflozin, Placebo |
| NCT02689843 | Effects of Treatment With Cyproterone Compound-spironolactone, Metformin and Pioglitazone on Serum Inflammatory Markers in Patients With Polycystic Ovary Syndrome (PCOS) | COMPLETED | INTERVENTIONAL | Cyproterone compound + Spironolactone, Metformin, Pioglitazone |
| NCT03151005 | Randomized Clinical Trial to Evaluate The Effect of Metformin-GLP-1 Receptor Agonist Versus Oral Contraceptive (OC) Therapy on Reproductive Disorders and Cardiovascular Risks in Overweight Polycystic Ovarian Syndrome (PCOS) Patients | COMPLETED | INTERVENTIONAL | Metformin-GLP-1 Receptor Agonist, Metformin-Oral Contraceptive(OC) |
| NCT00529542 | A Six-week Double Blinded, Randomized Trial of Atorvastatin for the Treatment of PCOS Women With Elevated LDL Cholesterol | COMPLETED | INTERVENTIONAL | Lipitor, Placebo |
| NCT00365638 | Effects of Simvastatin on Clinical, Endocrine, Metabolic and Biochemical Parameters of Women With Polycystic Ovary Syndrome: Prospective, Randomized Trial. | COMPLETED | INTERVENTIONAL | simvastatin |
| NCT00953355 | Effects of Metformin With or Without Folate Supplementation on Homocysteine Levels and Endothelium in Women With Polycystic Ovary Syndrome | COMPLETED | INTERVENTIONAL | Folate plus metformin, Placebo plus metformin |
| NCT06889454 | The Effect of Different Treatment Options on Markers of Vascular, Myocardial and Endothelial Function in Women With Polycystic Ovary Syndrome and the Association With Metabolic and Hormonal Abnormalities of the Syndrome | RECRUITING | OBSERVATIONAL | GLP-1 receptor agonist, Oral contraceptive, Metformin |
| NCT04979377 | Prevalence of Hyperandrogenism in Young Women With Type 1 Diabetes and Study of the Underlying Pathophysiological Mechanisms | COMPLETED | OBSERVATIONAL | Clinical hyperandrogenism assessment, Total testosterone (ng/dL), A1c (%) |
| NCT01600833 | To Association of Serum Ferrtin and Homocysteine Levels With Insulin Resistence and Metabolic Syndrome in Women With Polycystic Ovary Syndrome | COMPLETED | OBSERVATIONAL | |
| NCT00784615 | Descriptive, Transversal Study of Evaluation of Cardiovascular Risks Factors and Prevalence of Metabolic Syndrome in the Different Phenotypes of Women With Polycystic Ovary Syndrome | UNKNOWN | OBSERVATIONAL | Blood samples, transvaginal ultrasound |
| NCT00037245 | Androgens and Subclinical Atherosclerosis in Young Women - Ancillary to CARDIA | COMPLETED | OBSERVATIONAL | |
| NCT00005459 | Risk of Coronary Heart Disease in Women With Polycystic Ovary Syndrome | COMPLETED | OBSERVATIONAL |
Genetic associations (0)
None linked.